Activation of the prostaglandin E-2 EP2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices by Jensen, Michael Schou et al.
  
 University of Groningen
Activation of the prostaglandin E-2 EP2 receptor attenuates renal fibrosis in unilateral ureteral
obstructed mice and human kidney slices
Jensen, Michael Schou; Mutsaers, Henricus A. M.; Tingskov, Stine Julie; Christensen,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Jensen, M. S., Mutsaers, H. A. M., Tingskov, S. J., Christensen, M., Madsen, M. G., Olinga, P., ...
Norregaard, R. (2019). Activation of the prostaglandin E-2 EP2 receptor attenuates renal fibrosis in
unilateral ureteral obstructed mice and human kidney slices. Acta physiologica, 227(1), [e13291].
https://doi.org/10.1111/apha.13291
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Acta Physiologica. 2019;227:e13291.    |  1 of 13
https://doi.org/10.1111/apha.13291
wileyonlinelibrary.com/journal/apha
Received: 26 February 2019 | Revised: 15 April 2019 | Accepted: 26 April 2019
DOI: 10.1111/apha.13291  
R E G U L A R  P A P E R
Activation of the prostaglandin E2 EP2 receptor attenuates renal 
fibrosis in unilateral ureteral obstructed mice and human kidney 
slices
Michael Schou Jensen1 |   Henricus A. M. Mutsaers1 |   Stine Julie Tingskov1 |   
Michael Christensen1 |   Mia Gebauer Madsen2 |   Peter Olinga3 |   Tae‐Hwan Kwon4 |    
Rikke Nørregaard1
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiology Society
Michael Schou Jensen and Henricus A. M. Mutsaers contributed equally to this study. 
1Department of Clinical Medicine, Aarhus 
University, Aarhus, Denmark
2Department of Urology, Aarhus University 
Hospital, Aarhus, Denmark
3Department of Pharmaceutical Technology 
and Biopharmacy, University of Groningen, 
Groningen, the Netherlands
4Department of Biochemistry and Cell 
Biology, School of Medicine, Kyungpook 
National University, Daegu, Korea
Correspondence
Rikke Nørregaard, Department of Clinical 
Medicine, Aarhus University, Palle Juul‐




Hildur and Dagny Jacobsens Foundation, 
Grant/Award Number: 1295716-1; 
Lundbeckfonden, Grant/Award Number: 
R231-2016-2344 ; Det Frie Forskningsråd, 
Grant/Award Number: 6110-00231B; 
Aarhus Universitets Forskningsfond, Grant/
Award Number: AUFF-E-2015-FLS-8-69 
Abstract
Aim: Renal fibrosis plays a pivotal role in the development and progression of 
chronic kidney disease, which affects 10% of the adult population. Previously, it 
has been demonstrated that the cyclooxygenase‐2 (COX‐2)/prostaglandin (PG) sys-
tem influences the progression of renal injury. Here, we evaluated the impact of 
butaprost, a selective EP2 receptor agonist, on renal fibrosis in several models of 
kidney injury, including human tissue slices.
Methods: We studied the anti‐fibrotic efficacy of butaprost using Madin‐Darby 
Canine Kidney (MDCK) cells, mice that underwent unilateral ureteral obstruction 
and human precision‐cut kidney slices. Fibrogenesis was evaluated on a gene and 
protein level by qPCR and Western blotting.
Results: Butaprost (50  μM) reduced TGF‐β‐induced fibronectin (FN) expression, 
Smad2 phosphorylation and epithelial‐mesenchymal transition in MDCK cells. In 
addition, treatment with 4 mg/kg/day butaprost attenuated the development of fibro-
sis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a 
reduction in the gene and protein expression of α‐smooth muscle actin, FN and col-
lagen 1A1. More importantly, a similar anti‐fibrotic effect of butaprost was observed 
in human precision‐cut kidney slices exposed to TGF‐β. The mechanism of action 
of butaprost appeared to be a direct effect on TGF‐β/Smad signalling, which was 
independent of the cAMP/PKA pathway.
Conclusion: In conclusion, this study demonstrates that stimulation of the EP2 re-
ceptor effectively mitigates renal fibrogenesis in various fibrosis models. These find-
ings warrant further research into the clinical application of butaprost, or other EP2 
agonists, for the inhibition of renal fibrosis.
K E Y W O R D S
butaprost, cyclooxygenase‐2, precision‐cut kidney slices, prostaglandin E2 receptor, renal fibrosis
See Editorial Commentary: Sands,  J. M. 
2019. Translating kidney fibrosis: Role of 
the EP2 receptor. Acta Physiol. 227, e13318.
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1 |  INTRODUCTION
Chronic kidney disease (CKD) affects approximately 
10% of the adult population in developed countries.1 
Moreover, the global incidence of CKD is on the rise, 
and as a consequence the disease greatly impacts health 
care budgets. Renal fibrosis, which is characterized by 
the excessive production and deposition of extracellular 
matrix proteins by activated myofibroblasts, plays a piv-
otal role in the development and progression of CKD as 
well as in renal transplant failure.2 Fibrosis results in the 
loss of organ architecture and function, and is regarded 
as the most damaging process in CKD; yet, despite over-
whelming efforts, effective therapeutic targets have not 
been identified. Thus, an urgent and unmet clinical need 
remains.
Previously, it has been demonstrated that the cyclo-
oxygenase‐2 (COX‐2)/prostaglandin (PG) system plays 
a dominant role in the progression of renal injury.3-5 
COX enzymes catalyze the conversion of arachidonic 
acid into prostaglandins, including prostaglandin E2 
(PGE2), which is an important mediator of numerous 
physiological processes in the kidney, including renal 
hemodynamics as well as water and salt balance.3 PGE2 
exerts its biological activity by activating several G pro-
tein‐coupled prostanoid receptors, known as EP1‐EP4.6 
Several studies have demonstrated an important role 
for the EP1‐EP4 receptors in renal injury. Previously, 
it has been reported that EP1 deletion in mice reduced 
diabetes‐induced expression of the fibrotic markers fi-
bronectin and α‐actin.7 Furthermore, EP1 antagonism, 
using ONO8711, decreased fibronectin (FN) expression 
in mouse proximal tubule cells.7 In addition, deletion of 
EP2 increases baseline systolic blood pressure and causes 
salt‐sensitive hypertension, which is a known risk factor 
for renal damage.8 Interestingly, renal gene expression of 
both EP2 and EP4 is shown to be increased during renal 
fibrogenesis, suggesting that these receptors might play 
a protective role in the fibrotic process.4,9 This notion is 
supported by the fact that butaprost, a selective EP2 ag-
onist, inhibits TGF‐β1‐induced myofibroblast transition 
of human foetal lung fibroblasts.10 However, the efficacy 
of butaprost for the treatment of renal fibrosis remains to 
be elucidated.
In the current study, we investigated the impact of 
butaprost on renal fibrogenesis at the cell, tissue and 
organ levels using well‐established in vitro and in vivo 
models as well as a recently developed human model of 
renal fibrosis, viz. precision‐cut kidney slices (PCKS). 
This model is suitable for studying multicellular (patho-
logical) processes, eg, fibrosis, directly in human tissues 
since cellular heterogeneity as well as organ architecture 
are maintained in the slices.
2 |  RESULTS
2.1 | The EP2 agonist, butaprost, mitigates 
TGF‐β‐induced epithelial‐mesenchymal 
transition (EMT)
EMT is an integral part of the fibrotic process. Therefore, 
we evaluated the impact of butaprost on TGF‐β‐induced 
EMT in Madin‐Darby Canine Kidney (MDCK) cells, which 
express the EP2 receptor (Figure 1A). As shown in Figure 
1B, exposure of MDCK cells to TGF‐β caused a fourfold 
increase in FN protein expression, which was concentra-
tion‐dependently inhibited by butaprost. At the highest tested 
concentration (50 μM), butaprost almost completely blocked 
TGF‐β‐induced FN expression. Therefore, this concentration 
was used for the remainder of the study. In addition, Figure 
1 demonstrates that treatment with TGF‐β increased TGF‐β 
gene expression, stimulated Smad2 phosphorylation and in-
duced a spindle‐like morphology indicative of EMT, all of 
which could be inhibited by butaprost. Taken together, these 
findings indicate that butaprost mitigates TGF‐β/Smad sig-
nalling and EMT in MDCK cells.
Next, we investigated whether butaprost mitigated the pro‐
fibrotic effects of TGF‐β via the cAMP pathway, which has 
been shown to play a role in pulmonary fibrosis.10 It has been 
demonstrated that activation of the EP2 receptor increases 
intracellular cAMP levels.3 Indeed, treatment with butaprost 
markedly increased intracellular cAMP levels; however, this 
response was suppressed in presence of TGF‐β (Figure 2A). 
Since butaprost clearly affected cAMP levels, we evaluated 
whether this effect was due to changes in adenylate cyclase 
(AC) activity, the enzyme that converts ATP into cAMP. As 
shown in Figure 2B, exposure of MDCK cells to a combina-
tion of TGF‐β, butaprost and SQ22536 (an AC inhibitor) did 
not hamper the anti‐fibrotic effect of butaprost.
As inhibition of AC did not attenuate the effects of buta-
prost, we investigated if protein kinase A (PKA), the cAMP‐
dependent activator of cAMP response element‐binding 
protein (CREB), was involved in its activity. Exposure of 
MDCK cells to a combination of TGF‐β, butaprost and H89 
(a PKA inhibitor) did not reverse the anti‐fibrotic effect of 
butaprost (Figure 2C). These findings suggest that the impact 
of butaprost on fibrogenesis is unconstrained by the cAMP/
PKA signalling pathway.
2.2 | Butaprost attenuates unilateral 
ureteral obstruction (UUO)‐induced fibrosis 
in mice
Butaprost clearly reduced fibrogenesis in MDCK cells; 
therefore, we studied the anti‐fibrotic efficacy of this 
compound in a murine in vivo model of renal fibrosis, 
namely UUO. Following surgery, we did not observe any 
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changes in body weight in the four groups. However, the 
obstructed kidney from UUO mice appeared to be swollen 
and was increased in weight as compared to sham mice 
(Table 1). Administration of butaprost did not affect the 
weight of the obstructed kidney. In addition, plasma cre-
atinine, BUN as well as plasma sodium and potassium did 
not change between the four groups (Table 1). Next, we 
confirmed the presence of the EP2 receptor in the model 
using both qPCR and immunohistochemistry. After seven 
days of UUO, expression of the EP2 receptor markedly 
increased, both on mRNA and protein level (Figure 3). 
However, this was not significantly altered by butaprost 
treatment. Immunohistochemical staining of kidney sec-
tions revealed that EP2 receptor immunoreactive protein 
F I G U R E  1  Butaprost attenuates TGF‐β‐induced epithelial‐mesenchymal transition. (A) Gene expression was studied by RT‐PCR with 
(+) or without (−) reverse transcriptase (RT) enzyme. (B) MDCK cells were exposed to 5 ng/ml TGF‐β in the absence or presence of butaprost 
(10‐50 μM) for 24 h. FN protein expression was studied using western blotting (n = 3). (C) Gene expression was studied by qPCR. Relative 
expression was calculated using the reference gene GAPDH (n = 6). (D) Immunoblot analysis of the expression of pSmad2/Smad2 normalized to 
total protein (n = 6). (E) Representative microscopy images showing MCKD cell morphology. 10× magnification, scale bar is 100 μm. Data are 
presented as mean ± SEM. *P < 0.05
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was stronger in the UUO kidneys, as compared to sham‐
operated mice, and localized to the interstitial cells (Figure 
3C). To examine whether the increased EP2 receptor label-
ling was associated with myofibroblasts in the interstitium, 
we performed double immunofluorescent labelling with 
antibodies against the EP2 receptor (red) and the myofi-
broblast marker αSMA (green) in the obstructed kidney. 
As shown in Figure 4, EP2 receptor expression co‐localizes 
with αSMA indicating that the EP2 receptor is associated 
with interstitial myofibroblasts.
F I G U R E  2  Anti‐fibrotic effect of butaprost is independent of cAMP/PKA signalling. MDCK cells were exposed to 5 ng/ml TGF‐β in the 
absence or presence of butaprost (50 μM), SQ22536 (75 µM) or H89 (10 µM) for 24 h. (A) cAMP levels were determined in cell lysates via ELISA 
(n = 6). (B, C) FN protein expression was studied using western blotting (n = 5‐6). Data are presented as mean ± SEM. *P < 0.05
Groups Sham Sham + butaprost UUO UUO + butaprost
Bodyweight (BW) 
(g)




5.8 ± 0.1 6.3 ± 0.3 7.5 ± 0.4* 8.4 ± 0.1# 
Creatinine 
(µmol/L)
11.7 ± 0.8 10.6 ± 0.8 12.8 ± 1 11.3 ± 0.6
BUN (mmol/L) 7.5 ± 0.2 6.3 ± 0.4 8.7 ± 0.6 7.7 ± 0.5
Na (mmol/L) 149.6 ± 0.6 149.5 ± 0.5 150 ± 0.7 149.8 ± 0.4
K (mmol/L) 4.8 ± 0.1 4.8 ± 0.3 4.4 ± 0.1 4.5 ± 0.1
Values are presented as mean ± SEM. Sham: n = 6, sham + butaprost: n = 6, UUO: n = 8 and 
UUO + butaprost: n = 10.
*P < 0.05 compared to sham; 
#P < 0.05 compared to sham + butaprost. 
T A B L E  1  Functional data after UUO 
and butaprost treatment
   | 5 of 13JENSEN Et al.
Regarding the development of fibrosis, we observed a 
clear increase in the protein expression of FN and αSMA 
following UUO, and treatment with butaprost reverted the 
expression to sham levels (Figure 5A,B). Furthermore, 
qPCR revealed that 7  days of UUO caused a 25‐fold in-
crease in the gene expression of αSMA, a 17‐fold increase 
in FN gene expression and a 15‐fold increase in COL1A1 
gene expression. Treatment with butaprost significantly 
reduced the mRNA levels of both αSMA and COL1A1 
(Figure 5C‐E). In accordance, fluorescence microscopy 
revealed that UUO resulted in increased αSMA staining, 
which could be mitigated by treatment with butaprost 
(Figure 5F). Furthermore, as shown in Figure 5G‐I, UUO 
increased both interstitial and tubular volume, indicative 
of renal damage, which was prevented by butaprost treat-
ment. Thus, stimulation of the EP2 receptor attenuates 
UUO‐induced renal fibrosis in mice.
2.3 | Stimulation of the EP2 receptor 
mitigates fibrogenesis in human PCKS
Finally, we investigated whether the anti‐fibrotic effect of 
butaprost could also be observed in a novel translational 
fibrosis model, viz. human PCKS. As shown in Figure 6, 
treatment with 10 ng/ml TGF‐β for 48 hours induced a fi-
brotic response in the slices, resulting in a more than four-
fold increase in the gene expression of COL1A1, FN and 
αSMA (Figure 6A‐C), without affecting PCKS viability as 
evaluated by ATP measurements (Figure 6D). In addition, 
exposure to TGF‐β increased mRNA levels of the EP2 recep-
tor, in line with the results obtained in UUO mice (Figure 
7A). Moreover, qPCR revealed that butaprost significantly 
antagonized TGF‐β‐induced fibrogenesis, as illustrated by 
a reduced expression of all tested fibrosis markers (Figure 
7C‐E) without affecting PCKS viability (Figure 7B). To 
exclude the possibility that endogenous prostaglandins 
elicited the anti‐fibrotic effects contributed to butaprost 
we performed several experiments in the presence of in-
domethacin, an inhibitor of both COX‐1 and COX‐2. Our 
results demonstrated that butaprost, in the absence of en-
dogenous prostaglandins, still attenuated TGF‐β‐induced 
fibrogenesis (Figure 7F). In addition, fluorescence micros-
copy showed stronger αSMA staining in PCKS exposed to 
TGF‐β. Administration of butaprost and TGF‐β in combina-
tion diminished staining intensity as compared to treatment 
with TGF‐β alone (Figure 7G). Thus, butaprost also attenu-
ates TGF‐β‐induced fibrogenesis in a human model of renal 
fibrosis.
F I G U R E  3  Impact of UUO and butaprost on EP2 receptor expression in vivo. Mice were subjected to 7 days of UUO and treated with 
butaprost (4 mg/kg). (A) Gene expression was studied by qPCR. Relative expression was calculated using the reference gene 18S (n = 6‐10). (B) 
Cortical EP2 protein expression was studied using western blotting (n = 6‐10). (C) Representative immunohistochemistry images showing EP2 
expression. 20× magnification, scale bar is 50 μm. Arrows indicate EP2‐positive interstitial cells. Data are presented as mean ± SEM. *P < 0.05
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3 |  DISCUSSION
Renal fibrosis plays a pivotal role in the development and 
progression of CKD as well as in renal transplant failure. As 
a result, many strategies have been developed in the hope of 
slowing down or even reversing the fibrotic process. Even 
though several studies have been successful at the pre‐clini-
cal level, only limited advances have been made in the trans-
lation of these findings to the level of patient treatment.11 
The search for effective therapies is mainly hampered by the 
absence of relevant translational models of renal fibrosis. 
Here, we investigated the anti‐fibrotic efficacy of butaprost, 
a selective EP2 receptor agonist, using various renal fibrosis 
models including a recently developed human model of the 
disease, viz. PCKS.
Using a bottom‐up translational approach, we demon-
strated that butaprost successfully mitigated fibrogenesis 
in MDCK cells, UUO mice and human PCKS. To date, 
only a few studies have demonstrated renal protective ef-
fects of butaprost on a cellular level and, to the best of our 
knowledge, we are the first to unveil the positive effects of 
butaprost in a multicellular human PCKS model as well as 
in an in vivo model. On a cellular level, Liu and colleagues 
described that butaprost treatment prevented TGF‐β‐in-
duced injury in MPC5 mouse podocytes, as illustrated by 
an increased proliferation and expression of slit diaphragm 
genes (nephrin, podocin and CD2AP), as well as a reduc-
tion in apoptosis.12 In addition, it has been demonstrated 
that butaprost reduced TGF‐β‐induced proliferation of 
glomerular mesangial cells, thereby diminishing renal 
injury.13 Evidently, butaprost elicits protective effects in 
various renal cell types.
In our hands, butaprost attenuated TGF‐β–induced EMT 
in MDCK cells. Even though the contribution of EMT to 
fibrosis remains a subject of debate, phenotypic alterations 
reminiscent of EMT, also referred to as epithelial pheno-
typic changes, do play a role in the development of renal 
fibrosis.14-16
The beneficial effect of butaprost is not limited to the 
kidney. Several studies have reported that butaprost also pro-
tects against pulmonary fibrosis. Kolodsick and colleagues 
demonstrated that butaprost attenuated TGF‐β–induced myo-
fibroblast transition of IMR‐90 cells.10 In addition, butaprost 
has been shown to inhibit TGF‐β–induced CCN2/CTGF 
expression in lung fibroblasts.17 Furthermore, it has been 
demonstrated that butaprost reduces collagen synthesis in rat 
pulmonary fibroblasts and mitigates differentiation into my-
ofibroblasts.18 Conjointly, these data indicate that butaprost 
appears to be a promising candidate drug for the treatment of 
organ fibrosis.
It is well known that stimulation of the EP2 receptor 
leads to activation of the cAMP/PKA pathway, and also 
in our hands butaprost increased cAMP levels in MDCK 
cells. However, our results indicated that the anti‐fibrotic 
effect of butaprost is independent of cAMP/PKA signal-
ling. Interestingly, it has previously been demonstrated that 
cAMP is not necessary for butaprost‐mediated aquaporin‐2 
membrane targeting, which was thought to be a cAMP‐de-
pendent event,19 indicating that activation of the EP2 re-
ceptor might also affect other pathways. Our results further 
revealed that butaprost attenuated fibrosis by hampering 
F I G U R E  4  Expression of the 
EP2 receptor in fibrotic renal tissue. 
Mice were subjected to 7 days of UUO. 
Afterwards, the UUO kidney was harvested 
and used for fluorescence microscopy. 
Representative image of immunolabeling 
for (A) αSMA (green) and (B) the EP2 
receptor (red). (C, D) Representative image 
of co‐immunolabeling (αSMA, green; 
EP2 receptor, red) counterstained with 
DAPI (blue). 40× magnification, scale bar 
is 20 μm. Arrows indicate EP2‐positive 
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F I G U R E  5  Butaprost mitigates fibrosis in UUO mice. Mice were subjected to 7 days of UUO and treated with butaprost (4 mg/kg). (A) FN 
and (B) αSMA protein expression was studied using Western blot (n = 6). (C‐E) Gene expression was studied by qPCR. Relative expression was 
calculated using the reference gene 18S (n = 6‐10). (F) Representative images of immunolabeling for αSMA (green) counterstained with DAPI 
(blue). 20× magnification, scale bar is 50 μm. (G) Hematoxylin and eosin staining of renal cortical tissue. 20× magnification, scale bar is 50 μm. 
Quantification of (H) interstitial and (I) tubular volume (n = 4). Data are presented as mean ± SEM. *P < 0.05
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TGF‐β/Smad2 signalling. This observation is in line with 
the study by Neil et al, showing that PGE2 reduced Smad3 
expression and nuclear accumulation in normal and ma-
lignant mammary epithelial cells.20 Moreover, it has been 
demonstrated that EP2 mediates the suppressive effect of 
COX‐2 and PGE2 on TGF‐β‐induced Smad2/3 signalling 
in normal and malignant mammary epithelial cells as well 
as in Balb/C mice with mammary tumours.21 In addition, 
using human renal glomerular mesangial cells, it has been 
shown that PGE2 induced post‐translational modification of 
Smad2 and promoted Smad2/4 complex formation.22 These 
findings support the notion that EP2 receptor activation can 
directly influence TGF‐β/Smad signalling.
Here, we show that the EP2 receptor is expressed in 
interstitial myofibroblasts following UUO. The current 
understanding regarding the tissue distribution of the EP2 
receptor is very limited. Using Northern blot analysis of 
mRNA expression, it has been demonstrated that the re-
ceptor is mainly present in the uterus, lung and spleen, 
exhibiting only low mRNA levels in the kidney.23 In rabbit 
kidney, the receptor was detected in glomeruli, thin de-
scending limbs of Henle's loop as well as medullary and 
cortical collecting ducts.24 In the same study, it was re-
ported that EP2 receptor mRNA could be detected in cul-
tured renal medullary interstitial cells.24 In addition, in rat 
kidney, it has been shown that the EP2 receptor is mainly 
expressed in the descending thin limb of the loop of Henle 
and the vasa recta of the outer medulla.25 The described 
tissue expression is in line with the main function contrib-
uted to the EP2 receptor, namely renal salt and water han-
dling. However, the increased expression observed during 
injury and the presence of the receptor in activated fibro-
blasts, as shown in this study, suggest an additional role in 
renal protection.
Stimulation of the EP2 receptor causes vasodilation 
and increases renal blood flow (RBF).8 It is known that 
preservation of RBF can diminish UUO‐induced renal 
fibrosis.26 Therefore, it is possible that improving RBF 
is one of the mechanisms underlying the renoprotective 
action of butaprost in vivo. Still, the main mechanisms 
of action seem to be a direct impact on TGF‐β/Smad sig-
nalling since the anti‐fibrotic effect of butaprost was also 
clearly observed in models lacking RBF, viz. MDCK cells 
and hPCKS.
Our findings provide the first preclinical evidence that tar-
geting the EP2 receptor may prevent renal fibrosis, as such, 
the use of specific EP2 agonists may reduce the occurrence of 
cardiovascular and renal side effects associated with systemic 
targeting of COX‐2.
In conclusion, this study demonstrates that stimulation of 
the EP2 receptor effectively mitigates renal fibrogenesis in 
various models of kidney injury, mainly by targeting TGF‐β/
Smad signalling. These findings warrant further research into 
the clinical application of butaprost, or other EP2 agonists, for 
the treatment of renal fibrosis.
4 |  MATERIALS AND METHODS
4.1 | Ethics statement
The use of human tissue for the preparation of PCKS was 
approved by the Central Denmark Region Committees on 
F I G U R E  6  Expression of fibrosis 
markers in human PCKS. PCKS were 
exposed to TGF‐β (5 or 10 ng/ml) for 
24‐48 h. (A‐C) Gene expression was 
studied by qPCR. Relative expression was 
calculated using the reference gene RPL22 
(n = 4‐5). (D) Viability of PCKS after 
treatment with 10 ng/ml TGF‐β, assessed by 
ATP content of the slices (n = 5‐7). Data are 
presented as mean ± SEM. *P < 0.05
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Biomedical Research Ethics (Journal number 1‐10‐72‐211‐17) 
and The Danish Data Protection Agency. All participants 
gave written informed consent.
All animal experiments were performed accord-
ing to the Danish National Guidelines for animal 
care, and were approved by the Danish veterinary and 
F I G U R E  7  Butaprost attenuates TGF‐β‐induced fibrosis in human PCKS. PCKS were exposed to 10 ng/ml TGF‐β in the absence or presence 
of butaprost (50 μM) for 48 h. (A) EP2 receptor gene expression was studied by qPCR. Relative expression was calculated using the reference gene 
GAPDH (n = 4). (B) Viability of the slices after treatment assessed by ATP content of the slices (n = 7). (C‐E) Gene expression of fibrosis markers 
was studied by qPCR. Relative expression was calculated using the reference gene RPL22 (n = 7). (F) PCKS were also incubated with butaprost 
in the presence of indomethacin (10 µM), an inhibitor of both COX‐1 and COX‐2, to mitigate the influence of endogenous prostaglandins. (G) 
Representative images of immunolabeling for αSMA (green) counterstained with DAPI (blue). 20× magnification, scale bar is 50 μm. Data are 
presented as mean ± SEM. # and *P < 0.05 compared to control or TGF‐β, respectively
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food administration (Approval no. 2015‐15‐0201‐ 
00658).
4.2 | Cell culture
MDCK epithelial cells were used to evaluate the anti‐fibrotic 
efficacy of butaprost (Cayman, Cat. 13741) in vitro. The cells 
were grown in Dulbecco's Modified Eagle Medium contain-
ing 10% foetal bovine serum and 1% penicillin/streptomycin. 
Cells were cultured at 37°C in a 5% CO2 atmosphere. Before 
experiments, cells were grown to 80% confluence and then 
serum starved for 24 h. During experiments, the cells were 
treated for 24 h with TGF‐β (5 ng/ml), butaprost (10, 20 or 
50  µM), the adenylate cyclase inhibitor SQ22536 (75  µM), 
the protein kinase A inhibitor H89 (10 µM) or a combination 
hereof. Concentrations were based on previous dose‐finding 
studies performed in our lab. Butaprost and the inhibitors were 
added to the culture medium 30 min prior to exposure with 
TGF‐β.
4.3 | cAMP levels
MDCK cells were cultured with and without TGF‐β and 
butaprost for 24 h, during the last 30 min the phosphodiester-
ase inhibitor IBMX (0.5 mM; Sigma) was added. Afterwards, 
cells were lysed and intracellular cAMP levels were meas-
ured using a cAMP enzyme immunoassay kit (Sigma) ac-
cording to the manufacturer's instructions. All measurements 
were performed in triplicate.
4.4 | Experimental animals
Experiments were performed using male C57BL/6 mice, 
8  weeks of age and weighing 21  ±  2  g (Janvier Labs, Le 
Genest‐Saint‐Isle, France). All animals had ad libitum access 
to standard rodent chow (Altromin, Lage, Germany) and tap 
water. During the experiments, mice were housed in groups 
of 2‐3 mice/cage in a 12 h:12 h light‐dark cycle at a tempera-
ture of 21 ± 2°C and a humidity of 55 ± 5%. The animals 
were allowed to acclimatize to their cages 3‐4 days prior to 
surgery. A preliminary dose‐response study, using the fol-
lowing doses 1, 2 and 4  mg/kg/day, was performed using 
4 animals per group. Subsequently, the anti‐fibrotic effect 
of butaprost was validated in a larger cohort, as described 
below.
4.5 | Experimental design and 
surgical procedures
During surgery, mice were anesthetized with sevoflurane 
and placed on a heating pad to maintain an appropriate 
body temperature (37‐38°C). Through a midline abdominal 
incision, the left ureter was exposed and occluded with a 
6‐0 silk ligature. UUO was maintained for 7 days. A total 
of 30 mice were divided into 4 experimental groups: sham‐
operated (n = 6), sham‐operated receiving butaprost (4 mg/
kg/day; n = 6), 7‐day UUO receiving intraperitoneal saline 
injections (n = 8) and 7‐day UUO treated with butaprost 
(4  mg/kg/day; n  =  10). Butaprost, diluted in saline, was 
administered twice daily via intraperitoneal injection start-
ing at the day of the surgery. Dosing was based on previous 
dose‐finding studies performed in our lab. After 7 days, the 
kidneys were extracted and blood was collected via car-
diac puncture for further analysis. Biochemical analysis of 
blood samples was performed using a Roche Cobas 6000 
analyzer (Roche Diagnostic) and creatinine levels were de-
termined using the Creatinine Assay Kit (Sigma), accord-
ing to the manufacturer's instructions.
4.6 | Precision‐cut kidney slices
PCKS were prepared from functional (ie, eGFR > 60 ml/
min/1.73  m2) and macroscopically healthy renal corti-
cal tissue obtained from both male and female patients 
following tumour nephrectomies, as described previ-
ously.27 In short, slices were prepared in ice‐cold Krebs‐
Henseleit buffer, supplemented with 25  mM D‐glucose, 
25  mM NaHCO3, 10  mM 4‐(2‐hydroxyethyl)pipera-
zine‐1‐ethanesulfonic acid and saturated with carbogen 
(95% O2, 5% CO2), using a Krumdieck tissue slicer. 
Subsequently, PCKS were cultured in William's E me-
dium with GlutaMAX containing 10 mg/mL ciprofloxa-
cin and 2.7 g/L D‐(+)‐Glucose solution at 37°C in an 80% 
O2, 5% CO2 atmosphere while gently shaken. Medium 
was refreshed every 24 h. PCKS viability was assessed by 
determining the ATP content of the slices using the ATP 
Colorimetric/Fluorometric Assay Kit (Sigma), according 
to the manufacturer's instructions. Patient demographics 
are presented in Table 2.
4.7 | Western blotting
Total protein was extracted using either M‐PER mammalian 
protein extraction reagent (cells) or RIPA buffer (kidney 





Ischemia time (min) 42 ± 15
Values are presented as mean ± SD (n = 7).
BMI, body mass index; eGFR, estimated glomerular filtration rate.
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tissue), both supplemented with phosphatase‐inhibitor 2 and 
3 and a mini protease inhibitor tablet. Afterwards, 2% SDS 
and DTT were added to the samples, and they were heated 
for 15  min at 65°C. Total protein was separated by SDS/
PAGE using 12% Criterion TGX Stain‐free gels and subse-
quently blotted onto a nitrocellulose membrane. Afterwards, 
the membrane was blocked for 1 h with 5% skimmed milk in 
PBS‐T. The blot was then incubated overnight at 4°C with 
specific primary antibodies (Table 3). Afterwards, the mem-
brane was washed with PBS‐T and incubated with the ap-
propriate secondary antibody for 1 h at RT. Binding of the 
antibodies was visualized using ECL‐prime.
4.8 | Immunolabeling
Kidneys were fixed by perfusion through the left ventricle 
using 4% paraformaldehyde (PFA) in water. Afterwards, kid-
neys were immersed in 4% PFA for 1 h, rinsed with PBS, 
dehydrated using a graded series of alcohol and embedded 
in paraffin. Subsequently, tissue sections (2  μM) were de-
paraffinized, rehydrated, and then boiled in TEG‐buffer for 
16  min for epitope retrieval. Hereafter, sections were left 
to cool, and then incubated for 30 min in 50 mM NH4Cl to 
block free aldehyde groups. Afterwards, sections were incu-
bated with blocking solution (PBS containing 1% BSA, 0.2% 
gelatin and 0.05% saponin) for 30 min. For immunoperoxi-
dase labelling, the sections were incubated with a primary 
antibody against EP2 (Table 3) diluted in PBS with 0.1% 
BSA and 0.3% Triton‐X‐100 overnight at 4°C. Subsequently, 
the sections were washed three times with PBS containing 
0.1% BSA, 0.2% gelatine and 0.05% saponin followed by in-
cubation with a P448 secondary antibody diluted in washing 
solution for 1 h at RT. Afterwards, the sections were rinsed 
with PBS wash‐buffer, and the sites of antibody‐antigen reac-
tions were visualized with 0.05% 3,3′‐diaminobenzidine tet-
rachloride (Kem‐En‐Tec, Copenhagen, Denmark) dissolved 
in distilled water containing 0.1% H2O2. Light microscopy 
was performed using an Olympus BX50 light microscope 
and CellSens imaging software.
For immunofluorescence labelling, sections were covered 
with mouse‐on‐mouse blocking solution containing uncon-
jugated AffiniPure Fab Fragment Donkey Anti‐Mouse IgG 
(Jackson ImmunoResearch) in PBS for 1 h at RT and then 
fixed for 10 min in 4% PFA. Sections were incubated over-
night at 4°C with primary antibodies (EP2 and αSMA, Table 
3) diluted in PBS containing 0.1% BSA and 0.3% Triton 
X‐100. Sections were subsequently washed for 30  min in 
PBS containing 0.1% BSA, 0.2% gelatine, and 0.05% sa-
ponin and then incubated with Alexa Fluor 488 and Alexa 
Fluor 568‐conjugated secondary antibody at RT for 30 min 
(Life Technologies). Then, sections were counterstained with 
4,6‐diamidino‐2‐phenylindole (DAPI), washed with PBS, 
and mounted with SlowFade Gold Antifade Mountant (Life 
Technologies). Fluorescence microscopy was performed 
using an Olympus BX61 microscope and image processing 
was performed using Xcellence Rt software.
In addition, sections were stained with hematoxylin and 
eosin to assess kidney damage and tubular dilation. In order 
to evaluate tubule volume, a grid overlay was placed on each 
picture and tubules located at the points of intersections were 
marked. Afterwards, the lumen was measured in percentages 
of the marked area. Five pictures were captured in a blinded 
manner from each specimen at x20 magnification with no 
overlapping regions, and 6 tubules were assessed in each 
picture. Interstitial volume was calculated using ImageJ soft-
ware based on signal intensity of the αSMA immunolabeling.
4.9 | PCR
Total RNA was isolated using either TRIzol Reagent (cells) 
or a NucleoSpin RNA II mini kit (kidney tissue; Macherey 
Nagel), following the manufacturer's instructions. RNA was 
quantitated by spectrophotometry and stored at −80°C. cDNA 
was synthesized from 0.5 μg RNA with the RevertAid First 
Strand synthesis kit (Thermo Scientific). To confirm expres-
sion of the EP2 receptor in MDCK cells, RT‐PCR was per-
formed with (+) or without (−) reverse transcriptase (RT) 
enzyme. Afterwards, the PCR product was analysed by elec-
trophoresis using a 1% agarose gel run at 70 V for 45 min, 
including a marker (Generuler DNA marker, Invitrogen). 
Images of the gel were obtained with an Azure c200 gel im-
aging workstation. To study the expression level of the other 
genes of interest, qPCR was performed using 100 ng cDNA, 
which served as the template for PCR amplification using the 
Brilliant SYBR Green qPCR Master Mix (Thermo Scientific), 
according to the manufacturer's instructions. Used primers are 
listed in Table 4.
4.10 | Statistics
Statistics were performed using Graphpad Prism by either 
one‐way ANOVA followed by Tukey's or Dunnett's multi-
ple comparisons test, two‐way ANOVA followed by Tukey's 
post hoc test or using an unpaired two‐tailed Student's t test 
as appropriate. Differences between groups were considered 
to be statistically significant when P < 0.05.
T A B L E  3  Primary antibodies
Target Catalog nr Company Species Dilution
αSMA M0851 Dako Mouse 1:1000
FN ab2413 Abcam Rabbit 1:1000
EP2 ab167171 Abcam Rabbit 1:500
Smad2 5339 Cell Signalling Rabbit 1:1000
pSmad2 3108 Cell Signalling Rabbit 1:1000
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